TrialOncotarget2014

MRD assessed by WT1 and NPM1 transcript levels identifies distinct outcomes in AML patients and is influenced by gemtuzumab ozogamicin.

Juliette Lambert et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.